{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:07:26Z","timestamp":1793848046870,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T00:00:00Z","timestamp":1360368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1756-9966-32-8","type":"journal-article","created":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T07:15:07Z","timestamp":1360394107000},"source":"Crossref","is-referenced-by-count":52,"title":["Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma"],"prefix":"10.1186","volume":"32","author":[{"given":"Yong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,9]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.tibs.2005.10.003","volume":"30","author":"J Jin","year":"2005","unstructured":"Jin J, Cai Y, Li B, Conaway RC, Workman JL, Conaway JW, Kusch T: In and out: histone variant exchange in chromatin. Trends Biochem Sci. 2005, 30: 680-687. 10.1016\/j.tibs.2005.10.003.","journal-title":"Trends Biochem Sci"},{"key":"644_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature05915","volume":"447","author":"SL Berger","year":"2007","unstructured":"Berger SL: The complex languige of chromatin regulation during transcription. Nature. 2007, 447: 407-412. 10.1038\/nature05915.","journal-title":"Nature"},{"key":"644_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/nsmb1337","volume":"14","author":"SR Bhaumik","year":"2007","unstructured":"Bhaumik SR, Smith E, Shilatifard A: Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol. 2007, 14: 1008-1016. 10.1038\/nsmb1337.","journal-title":"Nat Struct Mol Biol"},{"key":"644_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0168-9525(03)00115-X","volume":"19","author":"MJ Carrouzza","year":"2003","unstructured":"Carrouzza MJ, Utley RT, Workman JL, Cote J: The divers functions of histone acetyltransferase complexes. Trends Genet. 2003, 19: 321-329. 10.1016\/S0168-9525(03)00115-X.","journal-title":"Trends Genet"},{"key":"644_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1128\/MCB.01045-07","volume":"28","author":"A Gupta","year":"2008","unstructured":"Gupta A, Guerin-Peyrou TG, Sharma GG, Park C, Agarwal M, Ganju RK, Pandita S, Choi K, Sukumar S, Pandita RK, Ludwig T, Pandita TK: The mammalian ortholog of Drosophla MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol. 2008, 28: 397-409. 10.1128\/MCB.01045-07.","journal-title":"Mol Cell Biol"},{"key":"644_CR6","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1128\/MCB.01476-09","volume":"30","author":"GG Sharma","year":"2010","unstructured":"Sharma GG, So S, Gupta A, Kumar R, Cayrou C, Avvakumov N, Bhadra U, Pandita RK, Porteus MH, Chen DJ, Cote J, Pandita TK: MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol. 2010, 30: 3582-3595. 10.1128\/MCB.01476-09.","journal-title":"Mol Cell Biol"},{"key":"644_CR7","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1038\/sj.onc.1210607","volume":"26","author":"S Rea","year":"2007","unstructured":"Rea S, Xouri G, Akhtar A: Males absent on the first (MOF): from flies to humans. Oncogene. 2007, 26: 5385-5394. 10.1038\/sj.onc.1210607.","journal-title":"Oncogene"},{"key":"644_CR8","doi-asserted-by":"publisher","first-page":"9175","DOI":"10.1128\/MCB.25.21.9175-9188.2005","volume":"25","author":"ER Smith","year":"2005","unstructured":"Smith ER, Cayrou C, Huang R, Lane WS, C\u00f4t\u00ea J, Lucchesi JC: A human protein complex homologus to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol. 2005, 25: 9175-9188. 10.1128\/MCB.25.21.9175-9188.2005.","journal-title":"Mol Cell Biol"},{"key":"644_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.molcel.2006.02.007","volume":"21","author":"S Mendjan","year":"2006","unstructured":"Mendjan S, Taipale M, Kind J, Holz H, Gebhardt P, Schelder M, Vermeulen M, Buscaino A, Duncan K, Mueller J, Wilm M, Stunnenberg HG, Saumweber H, Akhtar A: Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell. 2006, 21: 811-823. 10.1016\/j.molcel.2006.02.007.","journal-title":"Mol Cell"},{"key":"644_CR10","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1074\/jbc.C109.087981","volume":"285","author":"Y Cai","year":"2010","unstructured":"Cai Y, Jin J, Swanson SK, Cole MD, Choi SH, Florens L, Washburn MP, Conaway JW, Conaway RC: Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. J Biol Chem. 2010, 285: 4268-4272. 10.1074\/jbc.C109.087981.","journal-title":"J Biol Chem"},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.molcel.2006.11.026","volume":"24","author":"SM Sykes","year":"2006","unstructured":"Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB: Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006, 24: 841-851. 10.1016\/j.molcel.2006.11.026.","journal-title":"Mol Cell"},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"6798","DOI":"10.1128\/MCB.25.15.6798-6810.2005","volume":"25","author":"M Taiple","year":"2005","unstructured":"Taiple M, Rea S, Richter K, Vilar A, Lichter P, Imhof A, Akhtar A: hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol. 2005, 25: 6798-6810. 10.1128\/MCB.25.15.6798-6810.2005.","journal-title":"Mol Cell Biol"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2011.04.020","volume":"42","author":"P Mulligan","year":"2011","unstructured":"Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, N\u00e4\u00e4r AM: A SIRT-LSD1 Co-repressor complex regulates notch target gene expression and development. Mol Cell. 2011, 42: 689-699. 10.1016\/j.molcel.2011.04.020.","journal-title":"Mol Cell"},{"key":"644_CR14","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/emboj.2010.125","volume":"29","author":"M Orpinell","year":"2010","unstructured":"Orpinell M, Fournier M, Riss A, Nagy Z, Krebs AR, Frontini M, Tora L: The ATAC acetyl transferase complex controls mitotic progression by targeting non-histone substrates. EMBO J. 2010, 29: 2381-2394. 10.1038\/emboj.2010.125.","journal-title":"EMBO J"},{"key":"644_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ijc.23283","volume":"122","author":"S Pfister","year":"2008","unstructured":"Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A, Lichter P: The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2008, 122: 1207-1213.","journal-title":"Int J Cancer"},{"key":"644_CR16","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-08-3907","volume":"69","author":"S Elsheikh","year":"2009","unstructured":"Elsheikh S, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM, Ellis IO: Globle histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69: 3802-3809. 10.1158\/0008-5472.CAN-08-3907.","journal-title":"Cancer Res"},{"key":"644_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel E, Ward E, Murray T, Xu J, Thun MJ: Cancer stastistics. CA Cancer J Clin. 2007, 57: 43-66. 10.3322\/canjclin.57.1.43.","journal-title":"CA Cancer J Clin"},{"key":"644_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","volume":"30","author":"NK Janzen","year":"2003","unstructured":"Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recruitment disease. Urol Clin North Am. 2003, 30: 843-852. 10.1016\/S0094-0143(03)00056-9.","journal-title":"Urol Clin North Am"},{"key":"644_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.eururo.2009.01.003","volume":"55","author":"C Eichelberg","year":"2009","unstructured":"Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009, 55: 851-863. 10.1016\/j.eururo.2009.01.003.","journal-title":"Eur Urol"},{"key":"644_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eursup.2007.01.016","volume":"6","author":"AS Belldegrun","year":"2007","unstructured":"Belldegrun AS: Renal cell carcinoma: prognostic factors and patient selection. Eur Urol Suppl. 2007, 6: 477-483. 10.1016\/j.eursup.2007.01.016.","journal-title":"Eur Urol Suppl"},{"key":"644_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejso.2012.10.004","volume":"39","author":"XR Wu","year":"2012","unstructured":"Wu XR, Sha JJ, Liu DM, Chen YH, Yang GL, Zhang J, Xhen YY, Bo JJ, Huang YR: High expression of p53-induced ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma. Eur J Sur Oncol. 2012, 39: 100-106.","journal-title":"Eur J Sur Oncol"},{"key":"644_CR22","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1111\/j.1349-7006.2010.01717.x","volume":"101","author":"D Mosashvilli","year":"2010","unstructured":"Mosashvilli D, Kahl P, Mertens C, Holzapfel S, Rogenhofer S, Hauser S, B\u00fcttner R, Von Ruecker A, M\u00fcller SC, Ellinger J: Globle histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 2010, 101: 2664-2669. 10.1111\/j.1349-7006.2010.01717.x.","journal-title":"Cancer Sci"},{"key":"644_CR23","volume-title":"AJCC Cancer Staging Manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 2010, Chicago, IL: Springer, 7","edition":"7"},{"key":"644_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00428-011-1105-y","volume":"459","author":"M Choschzick","year":"2011","unstructured":"Choschzick M, Oosterwijl R, Muller V, Woelber L, Simon R, Moch H, Tennstedt P: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch. 2011, 459: 193-200. 10.1007\/s00428-011-1105-y.","journal-title":"Virchows Arch"},{"key":"644_CR25","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.ejca.2010.07.020","volume":"46","author":"J Tostain","year":"2010","unstructured":"Tostain J, Li G, Gentil-Perret A, Gigante M: Carbonate anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur J Cancer. 2010, 46: 3141-3148. 10.1016\/j.ejca.2010.07.020.","journal-title":"Eur J Cancer"},{"key":"644_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4132\/KoreanJPathol.2011.45.4.386","volume":"45","author":"JS Song","year":"2011","unstructured":"Song JS, Chun SM, Lee JY, Kim DK, Kim YH, Jang SJ: The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Korean J Pathol. 2011, 45: 386-396. 10.4132\/KoreanJPathol.2011.45.4.386.","journal-title":"Korean J Pathol"},{"key":"644_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","volume":"58","author":"AB Stillebroer","year":"2010","unstructured":"Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, daignosis, and therapy. Eur Urol. 2010, 58: 75-83. 10.1016\/j.eururo.2010.03.015.","journal-title":"Eur Urol"},{"key":"644_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/sj.bjc.6603530","volume":"96","author":"SA Hussain","year":"2007","unstructured":"Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH: Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer. 2007, 96: 104-109. 10.1038\/sj.bjc.6603530.","journal-title":"Br J Cancer"},{"key":"644_CR29","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cncr.24163","volume":"115","author":"T Klatte","year":"2009","unstructured":"Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ: Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009, 115: 1448-1458. 10.1002\/cncr.24163.","journal-title":"Cancer"},{"key":"644_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1200\/JCO.2003.11.132","volume":"21","author":"DE Swinson","year":"2003","unstructured":"Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Harris AL, O\u2019Byrne KJ: Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003, 21: 473-482. 10.1200\/JCO.2003.11.132.","journal-title":"J Clin Oncol"},{"key":"644_CR31","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1200\/JCO.2007.12.1087","volume":"25","author":"BC Leibovich","year":"2007","unstructured":"Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED: Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007, 25: 4757-4764. 10.1200\/JCO.2007.12.1087.","journal-title":"J Clin Oncol"},{"key":"644_CR32","first-page":"2827","volume":"57","author":"SY Liao","year":"1997","unstructured":"Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ: Identification of the MN\/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997, 57: 2827-2831.","journal-title":"Cancer Res"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-32-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-9966-32-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-32-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T08:37:25Z","timestamp":1548232645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-32-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-32-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,9]]},"article-number":"8"}}